SCHEMBL28755643

SCHEMBL28755643

Cn1c(=O)c2[nH]cnc2n(C2CCCCC2)c1=S

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATAD2 Q6PL18 1/20 0.49
ADORA2B P29275 6/20 0.48
ADORA3 P0DMS8 2/20 0.48
PDE4A P27815 9/20 0.48
PDE4B Q07343 9/20 0.48
PDE4C Q08493 9/20 0.48
PDE4D Q08499 9/20 0.48
ADORA2A P29274 8/20 0.48
ADORA1 P30542 2/20 0.48
PIK3CD O00329 1/20 0.48
ALPL P05186 1/20 0.48
TMIGD3 P0DMS9 1/20 0.48
CYP2C19 P33261 1/20 0.48
HIF1A Q16665 1/20 0.48
MAPK1 P28482 2/20 0.44
CYP1A2 P05177 2/20 0.44
MAPT P10636 2/20 0.44
LMNA P02545 1/20 0.44
JAK2 O60674 1/20 0.42
JAK1 P23458 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28752598 0.93 ATAD2 (0.53) ATAD2ADORA2BADORA3PDE4APDE4B
SCHEMBL7022545 0.79 ADORA2B (0.57) ATAD2ADORA2BADORA3PDE4APDE4B
SCHEMBL9807157 0.79 ATAD2 (0.64) ATAD2ADORA2BADORA3PDE4APDE4B
SCHEMBL5005966 0.75 ADORA2A (0.62) ADORA2BADORA3PDE4APDE4BPDE4C
SCHEMBL9351699 0.75 ADORA2B (0.55) ATAD2ADORA2BADORA3PDE4APDE4B
SCHEMBL10441214 0.74 ADORA2B (0.51) ATAD2ADORA2BADORA3PDE4APDE4B
SCHEMBL18127709 0.71 ADORA2B (0.50) ATAD2ADORA2BADORA3PDE4APDE4B
SCHEMBL5935784 0.71 ADORA3 (0.61) ADORA2BADORA3PDE4APDE4BPDE4C
SCHEMBL9354344 0.70 ADORA2B (0.47) ADORA2BADORA3PDE4APDE4BPDE4C
SCHEMBL24700880 0.69 ATAD2 (0.57) ATAD2ADORA2BADORA3PDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105687199-A MPO inhibitors for the treatment of huntington's disease and multiple system atrophy 阿斯利康(瑞典)有限公司 2016-06-22 CN claimed
CN-103638029-A MPO inhibitors for the treatment of huntington's disease and multiple system atrophy ASTRAZENECA AB 2014-03-19 CN claimed
CN-101062037-B Process for their preparation of thioxanthine derivatives, their use ASTRAZENECA AB 2011-05-25 CN claimed
CN-101873857-A MPO inhibitors for the treatment of Huntington's disease and multiple system atrophy ASTRAZENECA AB 2010-10-27 CN claimed
CN-100379737-C Thioxanthine derivatives as myeloperoxidase inhibitors ASTRAZENECA AB (SE) 2008-04-09 CN claimed
CN-101062037-A Thioxanthine derivatives, process for their preparation (variants), their use and composition containing them ASTRAZENECA AB (SE) 2007-10-31 CN claimed
CN-1646531-A Thioxanthine derivatives as myeloperoxidase inhibitors ASTRAZENECA AB (SE) 2005-07-27 CN claimed
CN-105687199-A MPO inhibitors for the treatment of huntington's disease and multiple system atrophy 阿斯利康(瑞典)有限公司 2016-06-22 CN disclosed
CN-103638029-A MPO inhibitors for the treatment of huntington's disease and multiple system atrophy ASTRAZENECA AB 2014-03-19 CN disclosed
CN-101062037-B Process for their preparation of thioxanthine derivatives, their use ASTRAZENECA AB 2011-05-25 CN disclosed
CN-101873857-A MPO inhibitors for the treatment of Huntington's disease and multiple system atrophy ASTRAZENECA AB 2010-10-27 CN disclosed
CN-100379737-C Thioxanthine derivatives as myeloperoxidase inhibitors ASTRAZENECA AB (SE) 2008-04-09 CN disclosed
CN-101062037-A Thioxanthine derivatives, process for their preparation (variants), their use and composition containing them ASTRAZENECA AB (SE) 2007-10-31 CN disclosed
CN-1646531-A Thioxanthine derivatives as myeloperoxidase inhibitors ASTRAZENECA AB (SE) 2005-07-27 CN disclosed